Publications
A selection of published articles and posters in peer-reviewed scientific journals presenting studies with the PreciseInhale® and its different exposure modules.
-
Poster
Using PreciseInhale for Controlled Volunteer Exposures with Aerosols Extracted from Clinical Inhalers
PreciseInhale® – in vivo exposurePer Gerde 1,2, Carl–Olof Sjöberg 1 Helen Bäckroos1 & Helena Litorp 3,4
-
Poster
Simulation lung dissolution – fast-tracking DPI development
DissolvIt® – Dissolution testsBeatriz Noriega–Fernandes 1,2, Maria Malmlöf 3, Per Gerde 3,4, M. Luisa Corvo 2 and Eunice Costa 1
-
Bioavailability of inhaled or ingested PFOA adsorbed to house dust
PreciseInhale® – in vivo exposure 06 2022 -
PLoS One. 2017 Jan 20;12(1):e0170428. doi: 10.1371/journal.pone.0170428. eCollection 2017.
Development of Combining of Human Bronchial Mucosa Models with XposeALI® for Exposure of Air Pollution Nanoparticles
XposeALI® – Cell culture exposure -
Part Fibre Toxicol. 2018 May 2;15(1):19. doi: 10.1186/s12989-018-0256-2.
Multi-cellular human bronchial models exposed to diesel exhaust particles: assessment of inflammation, oxidative stress and macrophage polarization
XposeALI® – Cell culture exposure -
Toxicol Sci. 2018 Jul 1;164(1):21-30. doi: 10.1093/toxsci/kfy053.
Air-Liquid Interface: Relevant In Vitro Models for Investigating Air Pollutant-Induced Pulmonary Toxicity
XposeALI® – Cell culture exposure -
Poster
RDD 2015
Inhalation Pharmacokinetics of a Respirable Formulation of a Selective PDE4 Inhibitor, CHF6001, in Three Exposure Models: Isolated Perfused Lung, Intratracheally Intubated, and Nose-Only Exposed Rat
PreciseInhale® – Isolated Perfused Lung (IPL)E. Selg et al.
-
Poster
SOT2016
Development of advanced 3D-models with human primary bronchial epithelial cells (PBEC) for exposure to nanoparticles present in air pollution
XposeALI® – Cell culture exposureL. Palmberg et al.
-
Poster
DDL 2017
Characterisation of aerosols from solution-based pressurised metered dose inhalers (pMDIs) when delivered by PreciseInhale®
PreciseInhale® – in vivo exposureW. Terakosolphan et al.
-
Poster
Exposure of the Tracheally Intubated Rat to Aerosolized Lunar Dust Surrogate JSC1A-vf
PreciseInhale® – in vivo exposureE. Selg et al.
-
Poster
ISAM 2017
Aerosolizing PulmoSolTM and PulmoSphereTM with the PreciseInhale® system
PreciseInhale® – in vivo exposureM. Nowenwik et al.
-
Poster
Operating the Aeroneb® Mesh Nebulizer Within the PreciseInhale® Platform
PreciseInhale® – in vivo exposureP. Gerde et al.
-
Poster
AIT 2017
Evaluating Impact of Inhaled Particle Size on PK Profile of AZD1 Using The PreciseInhale
PreciseInhale® – in vivo exposureS. Oag et al.
-
Poster
DDL 2017
Effect of Compressed Air Pressure on Particle Size Distribution During Aerosol Generation with Ultrafine TiO2
PreciseInhale® – in vivo exposureM. Malmlöf et al.
-
Poster
DDL 2017
Dissolution of Orally Inhaled Drugs using DissolvIt®: Influence of a Newly Designed Pre-Separator for Particle Collection
DissolvIt® – Dissolution testsB. Noriega et al.
-
Poster
SOT 2017
Comparison of dissolution/absorption profiles of CuO and Cu nanoparticles by using the in vitro dissolution ranking tool DissolvIt®
DissolvIt® – Dissolution testsM. Malmlöf et al.
-
Poster
DDL 2015
In Vitro – Ex Vivo Correlation of Fluticasone Propionate Pharmacokinetic Profiles
DissolvIt® – Dissolution testsM. Börjel et al.
-
Poster
RDD 2014
The DissolvIt: An in vitro evaluation of the dissolution and absorption of three Inhaled dry powder drugs in the lung
DissolvIt® – Dissolution testsM. Malmlöf et al.
-
Poster
RDD 2018
A Comparison of Dissolv It Dissolution Profiles of Particles Deposited with a New Generation Impactor or with a PreciseInhale Aerosol Generator
DissolvIt® – Dissolution testsM. Malmlöf et al.
-
Poster
RDD 2018
Biorelevant Dissolution Testing of Orally Inhaled Drugs: Adding a Newly Designed Pre-Separator to PreciseInhale®
DissolvIt® – Dissolution testsB. Noriega et al.
-
J Aerosol Med Pulm Drug Deliv. 2010 Oct;23(5):273-84. doi: 10.1089/jamp.2009.0790.
Delivering horseradish peroxidase as a respirable powder to the isolated, perfused, and ventilated lung of the rat: the pulmonary disposition of an inhaled model biopharmaceutical
PreciseInhale® – Isolated Perfused Lung (IPL) -
J Aerosol Med Pulm Drug Deliv. 2018 Feb;31(1):61-70. doi: 10.1089/jamp.2017.1369. Epub 2017 Aug 2.
Investigation of Lung Pharmacokinetic of the Novel PDE4 Inhibitor CHF6001 in Preclinical Models: Evaluation of the PreciseInhale Technology
PreciseInhale® – Isolated Perfused Lung (IPL) -
J Aerosol Med Pulm Drug Deliv. 2013 Aug;26(4):181-9. doi: 10.1089/jamp.2012.0971. Epub 2012 Oct 24.
Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate
PreciseInhale® – Isolated Perfused Lung (IPL) -
Journal of Aerosol Science, Volume 151, January 2021, 105698
In Vitro to ex Vivo/In Vivo Correlation (IVIVC) of dissolution kinetics from inhaled particulate solutes using air/blood barrier models: Relation between in vitro design, lung physiology and kinetic output of models
DissolvIt® – Dissolution tests -
J Aerosol Med Pulm Drug Deliv. 2013 Aug;26(4):181-9. doi: 10.1089/jamp.2012.0971. Epub 2012 Oct 24.
Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate
PreciseInhale® – in vivo exposure -
Nanomaterials (Basel). 2020 Mar 27;10(4):618. doi: 10.3390/nano10040618.
Dry Generation of CeO 2 Nanoparticles and Deposition onto a Co-Culture of A549 and THP-1 Cells in Air-Liquid Interface-Dosimetry Considerations and Comparison to Submerged Exposure
XposeALI® – Cell culture exposureFree PMC article
-
Nanotoxicology. 2019 Dec;13(10):1362-1379. doi: 10.1080/17435390.2019.1655600. Epub 2019 Aug 29.
Exposure of normal and chronic bronchitis-like mucosa models to aerosolized carbon nanoparticles: comparison of pro-inflammatory oxidative stress and tissue injury/repair responses
XposeALI® – Cell culture exposureJie Ji 1, Koustav Ganguly 1, Xenia Mihai 1, Jitong Sun 1, Maria Malmlöf 1 2, Per Gerde 1 2, Swapna Upadhyay 1, Lena Palmberg 1
-
Eur J Pharm Biopharm. 2019 Jun;139:213-223. doi: 10.1016/j.ejpb.2019.03.005. Epub 2019 Mar 9.
Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs
DissolvIt® – Dissolution testsMaria Malmlöf 1, Mattias Nowenwik 2, Kristof Meelich 3, Iwona Rådberg 2, Ewa Selg 2, John Burns 4, Hermann Mascher 3, Per Gerde 5
Journal of Aerosol Science -
Int J Pharm. 2021 Sep 25;607:121025. doi: 10.1016/j.ijpharm.2021.121025. Epub 2021 Aug 18.
Dry powder inhaler formulation comparison: Study of the role of particle deposition pattern and dissolution
DissolvIt® – Dissolution testsBeatriz Noriega-Fernandes 1, Maria Malmlöf 2, Mattias Nowenwik 3, Per Gerde 4, M Luisa Corvo 5, Eunice Costa 6
-
Mol Pharm. 2019 Mar 4;16(3):1245-1254. doi: 10.1021/acs.molpharmaceut.8b01200. Epub 2019 Feb 15.
Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products
DissolvIt® – Dissolution testsMireille Hassoun 1, Maria Malmlöf 2 3, Otto Scheibelhofer 4, Abhinav Kumar 1, Sukhi Bansal 1, Ewa Selg 2, Mattias Nowenwik 2, Per Gerde 2 3, Snezana Radivojev 4, Amrit Paudel 4 5, Sumit Arora 4, Ben Forbes 1
Free PMC article -
Assay Drug Dev Technol. Feb/Mar 2017;15(2):77-88. doi: 10.1089/adt.2017.779.
DissolvIt: An In Vitro Method for Simulating the Dissolution and Absorption of Inhaled Dry Powder Drugs in the Lungs
DissolvIt® – Dissolution testsPer Gerde 1 2, Maria Malmlöf 1 2, Lina Havsborn 1, Carl-Olof Sjöberg 3, Pär Ewing 4, Stefan Eirefelt 5, Katarina Ekelund 5
-
J Aerosol Med Pulm Drug Deliv. 2021 Aug;34(4):231-241. doi: 10.1089/jamp.2020.1637. Epub 2020 Nov 18.
Airway Epithelial Lining Fluid and Plasma Pharmacokinetics of Inhaled Fluticasone Propionate and Salmeterol Xinafoate in Mechanically Ventilated Pigs
PreciseInhale® – in vivo exposurePär Ewing 1, Steven Oag 2, Anders Lundqvist 1, Stina Stomilovic 1, Ida Stellert 2, Malin Antonsson 2, Sandro Filipe Nunes 2, Patrik U Andersson 3, Ulrika Tehler 4, Carl Sjöberg 5 6, AnnaMaria Péterffy 7, Per Gerde 6 8
-
J Aerosol Med Pulm Drug Deliv. 2010 Oct;23(5):273-84. doi: 10.1089/jamp.2009.0790.
Delivering horseradish peroxidase as a respirable powder to the isolated, perfused, and ventilated lung of the rat: the pulmonary disposition of an inhaled model biopharmaceutical
PreciseInhale® – in vivo exposureEwa Selg 1, Fernando Acevedo, Rolf Nybom, Bo Blomgren, Ake Ryrfeldt, Per Gerde
-
J Aerosol Med Pulm Drug Deliv. 2020 Apr;33(2):116-126. doi: 10.1089/jamp.2019.1554. Epub 2019 Oct 15.
Adapting the Aerogen Mesh Nebulizer for Dried Aerosol Exposures Using the PreciseInhale Platform
PreciseInhale® – in vivo exposurePer Gerde 1 2, Mattias Nowenwik 1, Carl-Olof Sjöberg 3, Ewa Selg 1
Free PMC article -
J Aerosol Med Pulm Drug Deliv. 2018 Feb;31(1):61-70. doi: 10.1089/jamp.2017.1369. Epub 2017 Aug 2.
Investigation of Lung Pharmacokinetic of the Novel PDE4 Inhibitor CHF6001 in Preclinical Models: Evaluation of the PreciseInhale Technology
PreciseInhale® – in vivo exposureAlessandro Fioni 1, Ewa Selg 2, Valentina Cenacchi 1, Fernando Acevedo 2, Giandomenico Brogin 1, Per Gerde 2 3, Paola Puccini 1
